A Maine overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
Maine's adult obesity rate reached 33.2% in 2024, according to the CDC's Behavioral Risk Factor Surveillance System (BRFSS) — up from 27.8% in 2011, a 5.4 percentage-point climb over 13 years of consistent state-level surveying 1. The state's population has grown alongside it, reaching 1,405,012 residents as of July 2024 (U.S. Census Bureau, Vintage 2024 estimates), its fourth consecutive year of population growth: +5,366 residents (+0.4%) over 2023 3.
That combination — more people, and a rising share of them living with obesity — is the backdrop against which Maine's GLP-1 coverage and access questions play out.
MaineCare, the state's Medicaid program, does not cover GLP-1 medications — semaglutide (Wegovy) or tirzepatide (Zepbound) — for obesity treatment under fee-for-service, according to the annual KFF survey of state Medicaid officials conducted with Health Management Associates in November 2025 and published by KFF on January 16, 2026 46.
Maine is one of 37 states or DC without this coverage; only 13 states currently pay for GLP-1s for obesity through Medicaid fee-for-service (Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin) 45. Maine's entry in KFF's coverage table carries no footnote or caveat marker, unlike several states with partial or conditional coverage — a clean 'not covered' response from MaineCare's own program officials 5.
This finding is specific to the obesity indication; MaineCare's handling of GLP-1s for type 2 diabetes, the medications' original and federally mandated use, is a separate question this research did not evaluate. We were unable to locate a MaineCare-published policy document (preferred drug list or pharmacy prior-authorization criteria) stating this exclusion directly — the finding rests on the KFF/HMA survey of state officials rather than a MaineCare-authored source, which is the strongest verification available at this time.
Because MaineCare doesn't pay for GLP-1s for weight loss, most Maine residents seeking this treatment pay out of pocket or through employer insurance with variable coverage. Astra's pricing is the same for patients in Maine as it is everywhere else in the country: $68 per month for semaglutide and $118 per month for tirzepatide, billed annually on a 12-month plan ($816 and $1,416 respectively). Astra does not set city- or state-specific prices — the plan cost is national and identical whether you're in Portland, Bangor, or anywhere else in Maine.
Physicians treating Maine patients are licensed through the Maine Board of Licensure in Medicine (allopathic) or the Maine Board of Osteopathic Licensure (osteopathic), which set the state's rules for telehealth practice, including prescribing across state lines. TODO: this research pass did not verify current telehealth-prescribing statute citations, effective dates, or interstate-practice specifics for either board — confirm directly with the board(s) before publishing rule-specific claims beyond basic licensure structure.
Astra is licensed to treat patients in all 50 states, including Maine. Residents don't need a specialist referral or an in-person visit to start — the full intake, consultation, and prescription process happens through telehealth.
Astra treats patients in Maine through state-licensed physicians.
City-level population, obesity, and local provider context for Maine.
No. As of a November 2025 survey of state Medicaid officials (published by KFF, January 2026), MaineCare does not cover GLP-1 medications for obesity treatment under fee-for-service. Only 13 states currently do. This applies to the weight-loss indication specifically; MaineCare's coverage for the type 2 diabetes indication is a separate question we haven't evaluated here.
No. Astra charges the same $68/month for semaglutide and $118/month for tirzepatide (billed annually at $816 and $1,416) everywhere in the country. There's no Maine markup and no Maine discount — the price is national.
Yes. Astra is licensed in all 50 states, including Maine, and treats patients entirely through telehealth — no in-person visit required.
Without MaineCare coverage, Maine residents typically pay out of pocket or rely on employer insurance, which varies by plan. Astra's flat national rate ($68/mo semaglutide, $118/mo tirzepatide on a 12-month plan) is one option; we didn't find a published, price-transparent local clinic market at the state level to compare against — that's a city-by-city question we address on Maine's city pages.
See our Portland, Maine page for city-level population, obesity, and local provider context.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.